Total cohort | Main study group, ≥ 3 days of survival | ||||||
---|---|---|---|---|---|---|---|
Total | Methadone in CSCI | No methadone in CSCI | |||||
n = 93 | n = 47 (13 + 34) | n = 13 | n = 34 | ||||
Day 0 | Day 0 | Day 3 | Day 0 | Day 3 | Day 0 | Day 3 | |
Level of pain (0–4)a | |||||||
Mean (SD) | 2.2 (1.1) | 2.2 (1.2) | 1.5 (1.2)*** | 2.9 (1.0) | 2.1 (1.3)* | 2.0 (1.1) | 1.2 (1.1)*** |
Median (IQR) | 2 (2) | 2 (2) | 2 (2) | 3 (1) | 2 (2) | 2 (2) | 1 (1) |
Severe to overwhelming pain (scores 3–4) n (%) | 39 (42) | 21 (45) | 9 (19)*** | 10 (77) | 6 (46)* | 11 (32) | 3 (9)*** |
MEDDb of opioids, mg | |||||||
Mean (SD) | 179 (175) | 184 (181) | 205 (182)* | 306 (257) | 354 (225) | 133 (108) | 142 (116)* |
Median (IQR) | 120 (169) | 123 (151) | 150 (210) | 240 (310) | 300 (193) | 113 (120) | 105 (125) |
Range | 22.5–1020 | 22.5–1020 | 30–870 | 22.5–1020 | 75–870 | 30–435 | 30–563 |
Methadone, mg | |||||||
Mean (SD) | 5.5 (4.6) | – | – | 7.5 (4.8) | 7.7 (4.5) | – | – |
Median (IQR) | 5 (7.5) | – | – | 5 (5) | 5 (5) | – | – |
Range | 0–20 | – | – | 2.5–20 | 5–20 | – | – |